Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brady

Showing results (531-540 of 627) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Nature Communications|October 10, 2018
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanismJames Peek, Mirjana Lilic, Daniel Montiel, et al.
American Journal of Medical Genetics. Part A|February 25, 2020
Clinical features, molecular results, and management of 12 individuals with the rare arthrochalasia Ehlers-Danlos syndromeSandy Ayoub, Neeti Ghali, Chloe Angwin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms resultsRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 24, 2020
Classical-like Ehlers-Danlos syndrome: a clinical description of 20 newly identified individuals with evidence of tissue fragilityClaire Green, Neeti Ghali, Rhoda Akilapa, et al.
Nature Chemical Biology|October 25, 2016
Discovery of MRSA active antibiotics using primary sequence from the human microbiomeJohn Chu, Xavier Vila-Farres, Daigo Inoyama, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Applied and Environmental Microbiology|June 1, 2000
Cloning the soil metagenome: a strategy for accessing the genetic and functional diversity of uncultured microorganismsM R Rondon, P R August, A D Bettermann, et al.
Pageof 63

Showing results (531-540 of 627) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Nature Communications|October 10, 2018
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanismJames Peek, Mirjana Lilic, Daniel Montiel, et al.
American Journal of Medical Genetics. Part A|February 25, 2020
Clinical features, molecular results, and management of 12 individuals with the rare arthrochalasia Ehlers-Danlos syndromeSandy Ayoub, Neeti Ghali, Chloe Angwin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms resultsRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 24, 2020
Classical-like Ehlers-Danlos syndrome: a clinical description of 20 newly identified individuals with evidence of tissue fragilityClaire Green, Neeti Ghali, Rhoda Akilapa, et al.
Nature Chemical Biology|October 25, 2016
Discovery of MRSA active antibiotics using primary sequence from the human microbiomeJohn Chu, Xavier Vila-Farres, Daigo Inoyama, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Applied and Environmental Microbiology|June 1, 2000
Cloning the soil metagenome: a strategy for accessing the genetic and functional diversity of uncultured microorganismsM R Rondon, P R August, A D Bettermann, et al.
Pageof 63